Eagle Pharmaceuticals (EGRX) Given Daily Media Sentiment Rating of 0.15
Media coverage about Eagle Pharmaceuticals (NASDAQ:EGRX) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eagle Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s analysis:
- Is Now the Time to Capitalize on Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) or Chesapeake Utilities Corporation … – FLBC News (flbcnews.com)
- Eagle Pharmaceuticals Inc (EGRX) Moves -1.55% – Stock Press Daily (stockpressdaily.com)
- Eagle Pharmaceuticals, Inc. (EGRX) Upgraded to “Buy” at BidaskClub (americanbankingnews.com)
- Proquest Associates Iv Holding in Eagle Pharmaceuticals (EGRX) Has Trimmed by $34.02 Million; As Exxon Mobil … – BZ Weekly (bzweekly.com)
- AcelRx Pharmaceuticals, Inc. (ACRX) noted a price change of 4.17 … – Stocks Gallery (stocksgallery.com)
Several research firms recently commented on EGRX. Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Royal Bank Of Canada set a $86.00 price target on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a report on Monday, April 24th. Piper Jaffray Companies set a $118.00 price target on shares of Eagle Pharmaceuticals and gave the company an “overweight” rating in a report on Tuesday, May 9th. ValuEngine upgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 16th. Finally, Mizuho restated an “underperform” rating and issued a $66.00 price target on shares of Eagle Pharmaceuticals in a report on Friday, March 17th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $90.00.
Eagle Pharmaceuticals (EGRX) traded up 0.81% during mid-day trading on Friday, hitting $81.68. 652,938 shares of the stock were exchanged. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of 12.84 and a beta of 1.48. The company has a 50 day moving average price of $78.99 and a 200 day moving average price of $77.77. Eagle Pharmaceuticals has a 52 week low of $34.20 and a 52 week high of $97.15.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Monday, May 8th. The specialty pharmaceutical company reported $1.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.44 by $0.02. Eagle Pharmaceuticals had a return on equity of 79.25% and a net margin of 44.48%. The company had revenue of $76.80 million during the quarter, compared to analyst estimates of $70.10 million. During the same quarter last year, the firm posted ($0.06) earnings per share. The firm’s revenue for the quarter was up 159.5% compared to the same quarter last year. Analysts expect that Eagle Pharmaceuticals will post $3.66 EPS for the current fiscal year.
In related news, major shareholder Proquest Investments Iv, L.P. sold 39,431 shares of the business’s stock in a transaction that occurred on Monday, March 27th. The stock was sold at an average price of $83.00, for a total value of $3,272,773.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Pete A. Meyers bought 350 shares of Eagle Pharmaceuticals stock in a transaction that occurred on Monday, June 12th. The stock was bought at an average price of $71.49 per share, with a total value of $25,021.50. Following the completion of the acquisition, the chief financial officer now owns 350 shares in the company, valued at approximately $25,021.50. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 805 shares of company stock valued at $61,790 and sold 297,593 shares valued at $25,001,116. 18.80% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “Eagle Pharmaceuticals (EGRX) Given Daily Media Sentiment Rating of 0.15” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/eagle-pharmaceuticals-egrx-given-daily-media-sentiment-rating-of-0-15/1390585.html.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.